Usana Health Sciences Shares Fall on Lowered Outlook, 3Q Revenue Decline

What happened

Usana Health Sciences lowered its full-year sales outlook to nearly $900 million from $910 million and its adjusted earnings forecast to 55 cents per share from 76 cents. Third-quarter revenue fell to $205.9 million from $213.7 million a year earlier.

Confirmed

Global impact / market context

Lower expected sales and adjusted earnings point to weaker near-term results than Usana previously forecast. If sales remain pressured, the company may have less revenue to cover operating costs and fund its stated investments in strengthening its businesses and developing its omnichannel health and wellness approach.

Analyst inference

The article reports a 10% after-hours share decline following the lowered outlook and quarterly revenue drop; it does not establish what caused the full-year sales weakness. Usana also reported a smaller quarterly loss than a year earlier, but an adjusted loss per share.

Confirmed

What to watch

1. Watch whether later reports show sales stabilizing after third-quarter revenue fell year over year, and whether actual full-year sales come close to the nearly $900 million outlook. Analyst inference
2. Compare future adjusted earnings with the 55-cents-per-share forecast; this measure excludes certain one-time items, so it may differ from the reported accounting result. Analyst inference
3. Look for evidence that investments in the omnichannel strategy strengthen sales or reduce costs, since the chief executive said results were mixed and some areas missed expectations. Analyst inference

Evidence

• Original source link unavailable